MTD Medical Technology and Devices S.A. agreed to acquire the Pen Needle and Blood Glucose Monitoring Businesses of Ypsomed Holding AG (SWX:YPSN) on March 27, 2024. The business with pen needles and BGMs to be transferred to MTD accounted for sales of CHF 52 million in FY 2022/23. The closing of the transaction is expected in summer 2024.

Stefan Brunnschweiler, Marquard Christen, Matthias Kuert, Mark Cagienard, Christian Gersbach, Dirk Spacek from CMS von Erlach Poncet and Alexandra Rohmert, Caroline Froger-Michon, Aliénor Fevre, Jean-Hugues de la Berge, William Hamon from CMS Francis Lefebvre Avocats and Heike Wagner, Tobias Kilian from CMS Cameron Mckenna Nabarro Olswang LLP acted as legal advisors to Ypsomed Holding AG (SWX:YPSN) in the transaction.